Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.

Pharvaris (NASDAQ: PHVS) reported positive topline results from the RAPIDe-3 pivotal Phase 3 study of oral deucrictibant IR 20 mg for on-demand treatment of hereditary angioedema (HAE) attacks.

The primary endpoint was met: median time to onset of symptom relief was 1.28 hours vs >12 hours for placebo (p<0.0001). All 11 secondary endpoints were significant, including End of Progression™ 17.47 minutes11.95 hours

Deucrictibant was well tolerated with no treatment-related serious adverse events; NDA filings are planned starting H1 2026.

Pharvaris (Nasdaq: PHVS) reported Q3 2025 results and a business update highlighting pivotal Phase 3 programs for deucrictibant. RAPIDe-3 (on-demand HAE, 20 mg immediate-release) reached ~120 participants and topline data are expected in 4Q2025. CHAPTER-3 (prophylaxis, 40 mg extended-release) enrollment is progressing with topline data anticipated in 2H2026. Pharvaris initiated CREAATE (AAE-C1INH pivotal study) and reported Phase 2 CHAPTER-1 OLE on-treatment attack rate of 0.12. Corporate financing included a public offering with proceeds of approximately $201 million. Cash and cash equivalents were €329 million as of September 30, 2025, providing runway into H1 2027. Q3 operating metrics: R&D €29.8M, G&A €9.8M, net loss €37.1M (loss per share €0.60).

Pharvaris (Nasdaq: PHVS) presented clinical and biomarker data at ACAAI 2025 highlighting deucrictibant's long-term safety, sustained efficacy, and a validated kinin assay.

Key data: open-label CHAPTER-1 extension showed treatment for up to ~34 months with mean attacks reduced from 2.18 to 0.12 attacks/month and an average 92.4% attack reduction; RAPIDe-2 Part A reported a median time-to-onset of symptom relief of 1.1 hours and median time-to-resolution of 10.6 hours with 89.2% of attacks resolved at 24 hours after a single dose.

The company also reported a clinically validated plasma kinin biomarker assay and reiterated expected pivotal readouts: CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025.

Pharvaris (Nasdaq: PHVS) announced acceptance of 2 oral and 6 poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.

Presentations focus on clinical data for oral deucrictibant in hereditary angioedema (prophylaxis and on‑demand treatment), biomarker assay validation, long‑term safety and efficacy (CHAPTER‑1 and RAPIDe‑2), and pharmacokinetics of an extended‑release tablet. Slides and posters will be posted on the company's investor website at presentation start times.

Pharvaris (NASDAQ:PHVS) reported Q2 2025 financial results and provided significant pipeline updates for its oral bradykinin B2 receptor antagonist programs. The company anticipates topline results from RAPIDe-3, a pivotal Phase 3 study for HAE attack treatment, in Q4 2025. Enrollment continues in CHAPTER-3, another Phase 3 study for HAE attack prophylaxis, with results expected in 2H 2026.

The company strengthened its financial position with €200 million in cash as of June 30, 2025, and subsequently raised $201 million through a public offering, extending its cash runway into 1H 2027. Q2 2025 financial results showed R&D expenses of €29.6 million and a net loss of €45.5 million (€0.83 per share).

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company, has successfully closed its upsized public offering, raising $201.2 million in gross proceeds. The offering included 9,562,500 ordinary shares (including the full exercise of underwriters' option for 1,312,500 additional shares) and pre-funded warrants to purchase 500,000 ordinary shares.

The offering was managed by a syndicate of investment banks including Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers. The securities were offered through an effective shelf registration statement previously filed with the SEC.

Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company focused on bradykinin-mediated diseases, has announced the pricing of an upsized public offering totaling $175 million. The offering consists of 8,250,000 ordinary shares priced at $20.00 per share and 500,000 pre-funded warrants at $19.99 per warrant.

The company has granted underwriters a 30-day option to purchase up to 1,312,500 additional ordinary shares. The offering, expected to close around July 24, 2025, is being managed by Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers.

Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company focused on bradykinin-mediated diseases, has announced a proposed public offering of $150 million in ordinary shares. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares.

The proceeds will fund research and development for late-stage clinical programs, establish a U.S. sales and marketing team, and support working capital needs. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are serving as joint book-running managers for the offering.